Randomized trial · people
Pramlintide lowered post-meal glucagon and glucose in type 2 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes, pramlintide blunted the glucagon spike after a meal, whether or not they used insulin.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 24
- Published
- 2002
- Journal
- Horm Metab Res
What they tested
The team tested whether pramlintide reduces the high levels of the hormone glucagon after meals that are common in people with type 2 diabetes.
How the study was done
A randomized, single-blind, placebo-controlled crossover trial in 24 people with type 2 diabetes: 12 used insulin and 12 did not. Each person had the same standard mixed meal on 2 occasions, once during a five-hour intravenous (into a vein) infusion of placebo and once during a pramlintide infusion at 100 microg/h, in random order.

What they found
With placebo, blood glucose and glucagon both rose a lot after the meal. With pramlintide, the post-meal rises in glucose and glucagon were both significantly smaller after the same meal (p < 0.05 for all). This held in both the insulin-treated and the non-insulin-treated groups. The authors concluded that lower glucagon likely helps explain how pramlintide lowers blood sugar after meals.
What it doesn’t show
This was a small trial with a single meal test on each treatment, using a five-hour intravenous infusion, so it does not show effects over weeks or months of use. The link between lower glucagon and lower blood sugar is the authors' interpretation, not something the trial tested directly.
The paper
Fineman et al. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002.
The compound
More studies on Pramlintide
- Pramlintide: HbA1c down 0.43% vs placebo at 26 weeks with insulinMeta-analysis · people · 2003
- Pramlintide-insulin loop: time in range held without carb countingRandomized trial · people · 2025
- Pramlintide-insulin mix: 2.1 kg more weight loss than lisproRandomized trial · people · 2024
- Pramlintide/insulin ADO09 cut meal glucose rise 69% in high-dose groupRandomized trial · people · 2023
- Pramlintide: weight loss maintained over 12 months in obesityRandomized trial · people · 2008
- Pramlintide: 3.7% placebo-corrected weight loss at 16 weeksRandomized trial · people · 2007
- Every study on Pramlintide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.